Furthermore, HDAC-based dual-target inhibitors, which simultaneously inhibit HDACs and other cancer-related pathways (e.g., PD-L1, SHP2, HSP90), have shown enhanced anti-tumor efficacy. This evidence concerns the gene HDAC9 and neoplasm.